The short version of REV-ERB fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-01-20. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
== Current Research and Future Implications == Currently, studies and experiments are being done to test for dedifferentiation-like abilities in mammalian cells, with hopes that this information can provide more insight into possible regenerative abilities in mammals. Dedifferentiation could spark innovation in regenerative medicine because it suggests that one's own cells can change cell fates, which would remove immunological response risks from treatment with allogeneic cells, or cells that are not genetically matched with the patient. A concept that has been explored for mammals is that of inducible dedifferentiation, which would make cells that do not naturally dedifferentiate be able to revert to a pluripotent or progenitor-like state. This is achieved by expressing the appropriate transcription factors in the cell and suppressing others. More information about this as well as the possible risks can be found here [1] .
2 November – Andy Street, the Mayor of the West Midlands, has written to the Home Secretary requesting that his office be granted the powers of the area's Police and Crime Commissioner after the next mayoral election because "crime in this region has more than doubled... and I simply cannot allow it to go on any longer". 5 November – The Metropolitan Police ends its relationship with adviser Attiq Malik after video emerged of him chanting a pro-Palestinian slogan during a speech to a group in 2021. Surrey County Council declares an emergency after thousands of properties are left without water following a technical problem at a Thames Water treatment works, which is attributed to Storm Ciarán. 7 November – Anastrozole, a drug used for a number of years to treat breast cancer, is licensed for use in England as a preventative option. West Yorkshire Police launch a murder investigation after a 15-year-old boy dies following a stabbing near a school in Leeds. He is later named as Alfie Lewis, a former student at Horsforth School. 9 November – A 14-year-old boy is remanded in custody charged with the murder of Alfie Lewis. Labour's Caroline Woodley is elected mayor of Hackney in London in a by-election. 10 November – Following trial and conviction at Leicester Crown Court, Katie Tidmarsh is sentenced to life imprisonment with a minimum term of 17 years for the 2012 murder of Ruby Thompson, a one-year-old child she had hoped to adopt.
== Prognosis == Quality of life is impacted severely and the prognosis of patients with Rabson–Mendenhall syndrome remains poor. This is due to the lack of a long-term treatment. Life expectancy is 1–2 years.
Sources: en.wikipedia.org
The government adopted a strategic hamlets policy of the kind used in Malaya and Vietnam to restrict the influence of insurgents over the population of rural areas. Local people were forced to relocate to protected villages (PVs) which were strictly controlled and guarded by the government against rebel atrocities. The protected villages were compared by the guerrillas to concentration camps. Some contemporary accounts claim that this interference in the lives of local residents induced many of them who had previously been neutral to support the guerrillas. The war degenerated into rounds of increasing brutality from all three parties involved (ZANU and ZAPU, and the Rhodesian Army). Mike Subritzky, a former New Zealand Army ceasefire monitor in Rhodesia, in 1980 described the war as "both bloody and brutal and brought out the very worst in the opposing combatants on all three sides." A major problem for the Rhodesian state in fighting the Bush War was always a shortage of manpower. Of the 3,000 white men liable for conscription in 1973, only about 1,000 reported when called-up. In February 1978, the Rhodesian Army stated it needed a minimum of 1,041 men to continue combat operations, and of those called up, only 570 reported for duty while the rest chose to move to South Africa. White emigration increased as the state called up more and more men to fight in the war, creating a vicious circle, which gradually limited the capacity of the Rhodesian state to continue the war.
=== Lifestyle === Regular exercise is recommended as both safe and effective to maintain muscle strength and overall physical function. Physical activity is beneficial for people with rheumatoid arthritis who experience fatigue, although there was little to no evidence to suggest that exercise may have an impact on physical function in the long term, a study found that carefully dosed exercise has shown significant improvements in patients with RA. Physical activity increases the production of synovial fluid, which lubricates the joints and reduces friction. Moderate effects have been found for aerobic exercises and resistance training on cardiovascular fitness and muscle strength in RA. Furthermore, physical activity had no detrimental side effects like increased disease activity in any exercise dimension. It is uncertain if eating or avoiding specific foods or other specific dietary measures help improve symptoms, but several studies have shown that high-vegetable diets improve RA symptoms, whereas high-meat diets make symptoms worse. Occupational therapy has a positive role to play in improving functional ability in people with rheumatoid arthritis. Weak evidence supports the use of wax baths (thermotherapy) to treat arthritis in the hands. Educational approaches that inform people about tools and strategies available to help them cope with rheumatoid arthritis may improve a person's psychological status and level of depression in the short term.
== Edman degradation == The Edman degradation is an alternative method for peptide sequencing that cleaves amino acid residues from the N-terminus of a peptide. In 1950 Edman designed a reaction with phenylthiocyanate (the idea for which was borrowed from a 1927 study by Bergmann, Kann and Miekeley ) to give phenylthiocarbamyl peptides followed by hydrolysis under relatively mild conditions to cleave N-terminal amino acid as phenylthiohydantoin. Phenylthiohydantoin is stable enough to undergo various sequencing procedures such as those which involve chromatography and mass spectrometry. This was an improvement on an earlier method proposed by Abderhalden and Brockmann in 1930 that demonstrated N-terminal amino acid conversion to a hydantoin under stronger hydrolytic conditions, where some cleavage of the residual peptide proved problematic. The primary advantage the Edman degradation has over the Bergmann degradation is the ease with which the residual peptide can re-enter the process due to retention of its structure throughout sequential cleaving. Repetition of the Bergmann degradation is presumably not as straightforward, as the remaining peptide is in amide form.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.